Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Rises By 5.7%

Aura Biosciences, Inc. (NASDAQ:AURAGet Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 1,300,000 shares, a growth of 5.7% from the August 15th total of 1,230,000 shares. Based on an average daily trading volume, of 174,700 shares, the days-to-cover ratio is presently 7.4 days. Currently, 3.1% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AURA shares. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Aura Biosciences in a research note on Friday. JMP Securities increased their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday. Finally, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th.

Read Our Latest Stock Report on Aura Biosciences

Institutional Trading of Aura Biosciences

Institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new position in shares of Aura Biosciences during the 2nd quarter worth $119,000. American International Group Inc. lifted its stake in shares of Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares during the last quarter. Virtu Financial LLC bought a new stake in Aura Biosciences in the first quarter worth $144,000. Trexquant Investment LP increased its position in Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after buying an additional 6,809 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Trading Down 1.0 %

AURA opened at $9.97 on Tuesday. The stock has a fifty day moving average price of $8.58 and a 200 day moving average price of $7.87. Aura Biosciences has a 1 year low of $5.99 and a 1 year high of $12.35. The stock has a market cap of $493.94 million, a price-to-earnings ratio of -5.36 and a beta of 0.35.

Aura Biosciences (NASDAQ:AURAGet Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. As a group, sell-side analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Aura Biosciences Company Profile

(Get Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Read More

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.